Who makes Low-dose ferric derisomaltose?

Low-dose ferric derisomaltose is developed by China-Japan Friendship Hospital.

What development phase is Low-dose ferric derisomaltose in?

Low-dose ferric derisomaltose is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

Low-dose ferric derisomaltose

China-Japan Friendship Hospital · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Low-dose ferric derisomaltose
Also known as	Less intensive target
Sponsor	China-Japan Friendship Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparing High and Low Dose Iron Treatments for People on Peritoneal Dialysis: The PALaDIN Study (PHASE3)
The Effects of Low-Dose Versus High-Dose Intravenous IRON Therapy With Ferric DerisomaltOSE in Patients With Chronic Heart Failure and Iron Deficiency (PHASE4)
Reducing Anemia in Pregnancy in India: the RAPIDIRON Trial (PHASE4)
RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low-dose ferric derisomaltose CI brief — competitive landscape report
Low-dose ferric derisomaltose updates RSS · CI watch RSS
China-Japan Friendship Hospital portfolio CI